

COVID-19 Impact on Global Benign Prostate Hyperplasia Drugs Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C91FFBD91424EN.html>

Date: August 2020

Pages: 96

Price: US\$ 3,900.00 (Single User License)

ID: C91FFBD91424EN

Abstracts

This report focuses on the global Benign Prostate Hyperplasia Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostate Hyperplasia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Sanofi

Coloplast

Pfizer

Merck

GlaxoSmithKline

Eli Lilly and Company

Abbott Laboratories

Teva Pharmaceuticals

Allergan

Boehringer Ingelheim

Market segment by Type, the product can be split into

Alpha Blocker

5-Alpha Reductase Inhibitor

Phosphodiesterase-5 Inhibitor

Others

Market segment by Application, split into

Hospital

Clinic

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Benign Prostate Hyperplasia Drugs status, future forecast, growth opportunity, key market and key players.

To present the Benign Prostate Hyperplasia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Benign Prostate Hyperplasia Drugs are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Benign Prostate Hyperplasia Drugs Revenue

1.4 Market Analysis by Type

1.4.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type:
2020 VS 2026

1.4.2 Alpha Blocker

1.4.3 5-Alpha Reductase Inhibitor

1.4.4 Phosphodiesterase-5 Inhibitor

1.4.5 Others

1.5 Market by Application

1.5.1 Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2020
VS 2026

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Other

1.6 Coronavirus Disease 2019 (Covid-19): Benign Prostate Hyperplasia Drugs Industry
Impact

1.6.1 How the Covid-19 is Affecting the Benign Prostate Hyperplasia Drugs Industry

1.6.1.1 Benign Prostate Hyperplasia Drugs Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Benign Prostate Hyperplasia Drugs Potential Opportunities in
the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Benign Prostate Hyperplasia Drugs Players to Combat Covid-19

Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Benign Prostate Hyperplasia Drugs Market Perspective (2015-2026)

2.2 Benign Prostate Hyperplasia Drugs Growth Trends by Regions

2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Benign Prostate Hyperplasia Drugs Historic Market Share by Regions (2015-2020)

2.2.3 Benign Prostate Hyperplasia Drugs Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Benign Prostate Hyperplasia Drugs Market Growth Strategy

2.3.6 Primary Interviews with Key Benign Prostate Hyperplasia Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Benign Prostate Hyperplasia Drugs Players by Market Size

3.1.1 Global Top Benign Prostate Hyperplasia Drugs Players by Revenue (2015-2020)

3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Players (2015-2020)

3.1.3 Global Benign Prostate Hyperplasia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio

3.2.1 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Benign Prostate Hyperplasia Drugs Revenue in 2019

3.3 Benign Prostate Hyperplasia Drugs Key Players Head office and Area Served

3.4 Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service

3.5 Date of Enter into Benign Prostate Hyperplasia Drugs Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2015-2020)

4.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2021-2026)

5 BENIGN PROSTATE HYPERPLASIA DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

5.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Benign Prostate Hyperplasia Drugs Market Size (2015-2020)

6.2 Benign Prostate Hyperplasia Drugs Key Players in North America (2019-2020)

6.3 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)

6.4 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2015-2020)

7.2 Benign Prostate Hyperplasia Drugs Key Players in Europe (2019-2020)

7.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)

7.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Benign Prostate Hyperplasia Drugs Market Size (2015-2020)

8.2 Benign Prostate Hyperplasia Drugs Key Players in China (2019-2020)

8.3 China Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)

8.4 China Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Benign Prostate Hyperplasia Drugs Market Size (2015-2020)

9.2 Benign Prostate Hyperplasia Drugs Key Players in Japan (2019-2020)

9.3 Japan Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)

9.4 Japan Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
- 10.2 Benign Prostate Hyperplasia Drugs Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
- 10.4 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
- 11.2 Benign Prostate Hyperplasia Drugs Key Players in India (2019-2020)
- 11.3 India Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
- 11.4 India Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
- 12.2 Benign Prostate Hyperplasia Drugs Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
- 12.4 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Sanofi

- 13.1.1 Sanofi Company Details
- 13.1.2 Sanofi Business Overview and Its Total Revenue
- 13.1.3 Sanofi Benign Prostate Hyperplasia Drugs Introduction
- 13.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- 13.1.5 Sanofi Recent Development

13.2 Coloplast

- 13.2.1 Coloplast Company Details
- 13.2.2 Coloplast Business Overview and Its Total Revenue
- 13.2.3 Coloplast Benign Prostate Hyperplasia Drugs Introduction
- 13.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business

(2015-2020)

13.2.5 Coloplast Recent Development

13.3 Pfizer

13.3.1 Pfizer Company Details

13.3.2 Pfizer Business Overview and Its Total Revenue

13.3.3 Pfizer Benign Prostate Hyperplasia Drugs Introduction

13.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)

13.3.5 Pfizer Recent Development

13.4 Merck

13.4.1 Merck Company Details

13.4.2 Merck Business Overview and Its Total Revenue

13.4.3 Merck Benign Prostate Hyperplasia Drugs Introduction

13.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)

13.4.5 Merck Recent Development

13.5 GlaxoSmithKline

13.5.1 GlaxoSmithKline Company Details

13.5.2 GlaxoSmithKline Business Overview and Its Total Revenue

13.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Introduction

13.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business

(2015-2020)

13.5.5 GlaxoSmithKline Recent Development

13.6 Eli Lilly and Company

13.6.1 Eli Lilly and Company Company Details

13.6.2 Eli Lilly and Company Business Overview and Its Total Revenue

13.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Introduction

13.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business

(2015-2020)

13.6.5 Eli Lilly and Company Recent Development

13.7 Abbott Laboratories

13.7.1 Abbott Laboratories Company Details

13.7.2 Abbott Laboratories Business Overview and Its Total Revenue

13.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Introduction

13.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business

(2015-2020)

13.7.5 Abbott Laboratories Recent Development

13.8 Teva Pharmaceuticals

13.8.1 Teva Pharmaceuticals Company Details

13.8.2 Teva Pharmaceuticals Business Overview and Its Total Revenue

13.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Introduction

13.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)

13.8.5 Teva Pharmaceuticals Recent Development

13.9 Allergan

13.9.1 Allergan Company Details

13.9.2 Allergan Business Overview and Its Total Revenue

13.9.3 Allergan Benign Prostate Hyperplasia Drugs Introduction

13.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)

13.9.5 Allergan Recent Development

13.10 Boehringer Ingelheim

13.10.1 Boehringer Ingelheim Company Details

13.10.2 Boehringer Ingelheim Business Overview and Its Total Revenue

13.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Introduction

13.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)

13.10.5 Boehringer Ingelheim Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Benign Prostate Hyperplasia Drugs Key Market Segments

Table 2. Key Players Covered: Ranking by Benign Prostate Hyperplasia Drugs Revenue

Table 3. Ranking of Global Top Benign Prostate Hyperplasia Drugs Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Alpha Blocker

Table 6. Key Players of 5-Alpha Reductase Inhibitor

Table 7. Key Players of Phosphodiesterase-5 Inhibitor

Table 8. Key Players of Others

Table 9. COVID-19 Impact Global Market: (Four Benign Prostate Hyperplasia Drugs Market Size Forecast Scenarios)

Table 10. Opportunities and Trends for Benign Prostate Hyperplasia Drugs Players in the COVID-19 Landscape

Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 12. Key Regions/Countries Measures against Covid-19 Impact

Table 13. Proposal for Benign Prostate Hyperplasia Drugs Players to Combat Covid-19 Impact

Table 14. Global Benign Prostate Hyperplasia Drugs Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 15. Global Benign Prostate Hyperplasia Drugs Market Size by Regions (US\$ Million): 2020 VS 2026

Table 16. Global Benign Prostate Hyperplasia Drugs Market Size by Regions (2015-2020) (US\$ Million)

Table 17. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2015-2020)

Table 18. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 19. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2021-2026)

Table 20. Market Top Trends

Table 21. Key Drivers: Impact Analysis

Table 22. Key Challenges

Table 23. Benign Prostate Hyperplasia Drugs Market Growth Strategy

Table 24. Main Points Interviewed from Key Benign Prostate Hyperplasia Drugs Players

Table 25. Global Benign Prostate Hyperplasia Drugs Revenue by Players (2015-2020)
(Million US\$)

Table 26. Global Benign Prostate Hyperplasia Drugs Market Share by Players
(2015-2020)

Table 27. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type
(Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs
as of 2019)

Table 28. Global Benign Prostate Hyperplasia Drugs by Players Market Concentration
Ratio (CR5 and HHI)

Table 29. Key Players Headquarters and Area Served

Table 30. Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service

Table 31. Date of Enter into Benign Prostate Hyperplasia Drugs Market

Table 32. Mergers & Acquisitions, Expansion Plans

Table 33. Global Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
(Million US\$)

Table 34. Global Benign Prostate Hyperplasia Drugs Market Size Share by Type
(2015-2020)

Table 35. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type
(2021-2026)

Table 36. Global Benign Prostate Hyperplasia Drugs Market Size Share by Application
(2015-2020)

Table 37. Global Benign Prostate Hyperplasia Drugs Market Size by Application
(2015-2020) (Million US\$)

Table 38. Global Benign Prostate Hyperplasia Drugs Market Size Share by Application
(2021-2026)

Table 39. North America Key Players Benign Prostate Hyperplasia Drugs Revenue
(2019-2020) (Million US\$)

Table 40. North America Key Players Benign Prostate Hyperplasia Drugs Market Share
(2019-2020)

Table 41. North America Benign Prostate Hyperplasia Drugs Market Size by Type
(2015-2020) (Million US\$)

Table 42. North America Benign Prostate Hyperplasia Drugs Market Share by Type
(2015-2020)

Table 43. North America Benign Prostate Hyperplasia Drugs Market Size by Application
(2015-2020) (Million US\$)

Table 44. North America Benign Prostate Hyperplasia Drugs Market Share by
Application (2015-2020)

Table 45. Europe Key Players Benign Prostate Hyperplasia Drugs Revenue

(2019-2020) (Million US\$)

Table 46. Europe Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)

Table 47. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US\$)

Table 48. Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)

Table 49. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US\$)

Table 50. Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)

Table 51. China Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US\$)

Table 52. China Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)

Table 53. China Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US\$)

Table 54. China Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)

Table 55. China Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US\$)

Table 56. China Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)

Table 57. Japan Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US\$)

Table 58. Japan Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)

Table 59. Japan Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US\$)

Table 60. Japan Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)

Table 61. Japan Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US\$)

Table 62. Japan Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)

Table 63. Southeast Asia Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US\$)

Table 64. Southeast Asia Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)

Table 65. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US\$)

Table 66. Southeast Asia Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)

Table 67. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US\$)

Table 68. Southeast Asia Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)

Table 69. India Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US\$)

Table 70. India Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)

Table 71. India Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US\$)

Table 72. India Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)

Table 73. India Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US\$)

Table 74. India Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)

Table 75. Central & South America Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US\$)

Table 76. Central & South America Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)

Table 77. Central & South America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US\$)

Table 78. Central & South America Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)

Table 79. Central & South America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US\$)

Table 80. Central & South America Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)

Table 81. Sanofi Company Details

Table 82. Sanofi Business Overview

Table 83. Sanofi Product

Table 84. Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 85. Sanofi Recent Development

Table 86. Coloplast Company Details

Table 87. Coloplast Business Overview

Table 88. Coloplast Product

Table 89. Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business

(2015-2020) (Million US\$)

Table 90. Coloplast Recent Development

Table 91. Pfizer Company Details

Table 92. Pfizer Business Overview

Table 93. Pfizer Product

Table 94. Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 95. Pfizer Recent Development

Table 96. Merck Company Details

Table 97. Merck Business Overview

Table 98. Merck Product

Table 99. Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 100. Merck Recent Development

Table 101. GlaxoSmithKline Company Details

Table 102. GlaxoSmithKline Business Overview

Table 103. GlaxoSmithKline Product

Table 104. GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 105. GlaxoSmithKline Recent Development

Table 106. Eli Lilly and Company Company Details

Table 107. Eli Lilly and Company Business Overview

Table 108. Eli Lilly and Company Product

Table 109. Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 110. Eli Lilly and Company Recent Development

Table 111. Abbott Laboratories Company Details

Table 112. Abbott Laboratories Business Overview

Table 113. Abbott Laboratories Product

Table 114. Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 115. Abbott Laboratories Recent Development

Table 116. Teva Pharmaceuticals Business Overview

Table 117. Teva Pharmaceuticals Product

Table 118. Teva Pharmaceuticals Company Details

Table 119. Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 120. Teva Pharmaceuticals Recent Development

Table 121. Allergan Company Details

Table 122. Allergan Business Overview

Table 123. Allergan Product

Table 124. Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 125. Allergan Recent Development

Table 126. Boehringer Ingelheim Company Details

Table 127. Boehringer Ingelheim Business Overview

Table 128. Boehringer Ingelheim Product

Table 129. Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US\$)

Table 130. Boehringer Ingelheim Recent Development

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Benign Prostate Hyperplasia Drugs Market Share by Type: 2020 VS 2026

Figure 2. Alpha Blocker Features

Figure 3. 5-Alpha Reductase Inhibitor Features

Figure 4. Phosphodiesterase-5 Inhibitor Features

Figure 5. Others Features

Figure 6. Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2020 VS 2026

Figure 7. Hospital Case Studies

Figure 8. Clinic Case Studies

Figure 9. Other Case Studies

Figure 10. Benign Prostate Hyperplasia Drugs Report Years Considered

Figure 11. Global Benign Prostate Hyperplasia Drugs Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 12. Global Benign Prostate Hyperplasia Drugs Market Share by Regions: 2020 VS 2026

Figure 13. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2021-2026)

Figure 14. Porter's Five Forces Analysis

Figure 15. Global Benign Prostate Hyperplasia Drugs Market Share by Players in 2019

Figure 16. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2019)

Figure 17. The Top 10 and 5 Players Market Share by Benign Prostate Hyperplasia Drugs Revenue in 2019

Figure 18. North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. Europe Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. China Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. Japan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)

- Figure 23. India Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 24. Central & South America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 25. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 26. Sanofi Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 27. Coloplast Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 28. Coloplast Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 29. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 30. Pfizer Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 31. Merck Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 32. Merck Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 33. GlaxoSmithKline Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 34. GlaxoSmithKline Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 35. Eli Lilly and Company Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 36. Eli Lilly and Company Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 37. Abbott Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 38. Abbott Laboratories Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 39. Teva Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 40. Teva Pharmaceuticals Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 41. Allergan Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 42. Allergan Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 43. Boehringer Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 44. Boehringer Ingelheim Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
- Figure 45. Bottom-up and Top-down Approaches for This Report
- Figure 46. Data Triangulation

Figure 47. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Benign Prostate Hyperplasia Drugs Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C91FFBD91424EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C91FFBD91424EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

